Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The hellenic experience

Abstract: Extracorporeal photopheresis (ECP) is an established therapy for cutaneous T-cell lymphoma (CTCL). The objective of this study was to further explore the clinical efficacy of ECP combined with immunomodulatory agents. Eighteen patients with histologically proven CTCL were followed-up after therapy with ECP, mainly combined with interferon-α or bexarotene. A total of 61% of patients responded to therapy (n =11; CR: 5, PR: 6). Median survival was 51months, progression free survival was 28months and response duration was 29±23.9months. ECP combined therapy was highly effective or had a palliative effect in CTCL resistant to previous treatments. [Copyright &y& Elsevier]